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Abstract: The light information pathways and their relationship with the body rhythms 
have generated a new insight into the neurobiology and the neurobehavioral sciences, as well 
as into the clinical approaches to human diseases associated with disruption of circadian 
cycles. Light-based strategies and/or drugs acting on the circadian rhythms have widely 
been used in psychiatric patients characterized by mood-related disorders, but the timing 
and dosage use of the various treatments, although based on international guidelines, are 
mainly dependent on the psychiatric experiences. Further, many efforts have been made to 
identify biomarkers able to disclose the circadian-related aspect of diseases, and therefore 
serve as diagnostic, prognostic, and therapeutic tools in clinic to assess the different mood-
related symptoms, including pain, fatigue, sleep disturbance, loss of interest or pleasure, 
appetite, psychomotor changes, and cognitive impairments. Among the endogenous factors 
suggested to be involved in mood regulation, the neurotrophins, nerve growth factor, and 
brain-derived neurotrophic factor show anatomical and functional link with the circadian 
system and mediate some of light-induced effects in brain. In addition, in humans, both 
nerve growth factor and brain-derived neurotrophic factor have showed a daily rhythm, 
which correlate with the morningness–eveningness dimensions, and are influenced by light, 
suggesting their potential role as biomarkers for chronotypes and/or chronotherapy. The 
evidences of the relationship between the diverse mood-related disorders, with a specific 
focus on depression, and neurotrophins are reviewed and discussed herein in terms of their 
circadian significance, and potential translation into clinical practice.
Keywords: retinal ganglional cells, mesocorticolimbic circuits, chronotherapy, ocular eye drops 
administration, neurotrophins
Neuroanatomical correlates of time, light, 
and mood
In humans, circadian (from the Latin word “circa diem”, meaning “about a day”) 
variations characterize multiple physiological and psychological functions, includ-
ing core body temperature, endocrine and autonomic functions, sleep, mood, 
alertness, and cognitive performance (Figure 1).1,2 Sleep and wakefulness are 
the most obvious manifestations of the mammalian circadian system: during the 
day, light supports all the activities, while during the night, sleep is crucial for 
restoring the body and mind (cellular repair and mental recovery).2 The coordi-
nator center of this system is the suprachiasmatic nucleus (SCN) located in the 
ventral hypothalamus (HYP) which receives direct projections from the retina and 
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represents the master clock. All SCN neurons are coupled 
by autocrine/paracrine signals and by synaptic signals, and 
oscillate in coordinate manner to regulate the peripheral 
oscillators directly through the sympathetic and parasym-
pathetic pathways, and indirectly by hormones, cytokines, 
and growth factors secretion.3,4 Conversely, signals arising 
from the periphery reach the brain and drive feedback 
information from the entire body in order to adapt the 
SCN activity, and generate a coherent functional network 
to regulate behaviors and physiology.
Important features of the SCN clock are its resilience 
to photic cues and the shifting phase during the dark phase, 
which guarantee the adaptation to geophysical time or envi-
ronmental changes without generating a constant modifica-
tion during the light phase. This is possible because although 
light is the most potent entraining cue, not all the light signals 
from the retina are capable of phase entrainment. Indeed, 
only a restricted number of retinal ganglion cells (RGCs), the 
intrinsically photosensitive retinal ganglion cells (ipRGCs) 
in the inner retina layer, contribute to regulate the circadian 
system.5,6 These cells express the light receptor melanopsin 
also in the absence of any other retinal input, and regener-
ate their chromophore without involving other cells.7,8 They 
constitute ∼4%–5% of all RGCs, projecting to image-forming 
brain areas (M2-4-5 ipRGC types), also serving as a relay 
station for the rods and cones, and nonimage-forming (NIF) 
brain areas (M1 ipRGC type). Further, ipRGCs are most 
sensitive to short-wavelength (∼480 nm) blue light, remain 
functional in the absence of rods and cones, and are resistant 
to injury.8 These properties guarantee that even in blind-
ness or severe ocular pathological conditions, the ipRGCs 
might convey light signals to the brain, and indicate that the 
ipRGCs-mediated effects do not require the fine spatial acuity 
necessary for image formation.9
The NIF effects of light include heart rate and pupil diam-
eter, the entrainment of circadian rhythms, and modulation 
of locomotor activity, as well as high-level cognitive and 
emotional processes.10
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Figure 1 Circadian time structure in persons adhering to a normal routine of daytime activity (from ∼6–7 am to ∼10–11 pm) alternating with nighttime sleep and a pre- and 
post-sleeping time (blue dashed pattern areas).
Notes: The circadian rhythms of TSH, GH, prolactin, ANP in blood peak between bedtime and early hours of sleep, while ACTH, FSH, LH, testosterone, cortisol, 
catecholamines, and aldosterone peak near the end of nighttime sleep or start of daytime activity. The starting and stopping times of melatonin secretion are indicated by red 
arrows at 9 pm and 7.30 am, respectively. The lower and high levels of different body functions, including temperature, blood pressure, and cardiac and bowel activity, are 
indicated by orange arrows. The trend of ultradian NGF and BDNF levels in humans serum is also reported irrespective of sex difference.
Abbreviations: ACTH, adrenocortical tropic hormone; ANP, atrial natriuretic peptide; BDNF, brain-derived neurotrophic factor; FSH, follicle-stimulating hormone; GH, 
growth hormone; LH, luteinizing hormone; NGF, nerve growth factor; TSH, thyroid-stimulating hormone.
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Figure 2 Circadian, reward, and depression integrated network.
Notes: The major brain structures and pathways involved in light/timing signals (yellow), reward (blue), and depression (red) are shown. The SCN, the PiN, and the HB 
receive directly projections from the RGCs, but their activities are also modulated by the reward system via the vTA and the NAc. The circadian rhythm and functions 
of the hypothalamic nuclei, including awaking, alert, arousal, and feeding, are regulated by light signals through the SCN and by the reward system through the vTA/NAc 
network. In addition, ipRGCs project to the AMY, HB, and thalamus and PVN, thus influencing directly depression and anxiety. The complex network between the cortex, 
the forebrain, and the brainstem structures involved in mood, pain, timing, and reward contributes to integrate the internal and external signals into a mental/body rhythm, 
which characterizes an individual and identifies his specific physiological or pathological condition.
Abbreviations: ACC, anterior cingulate cortex; AMY, amygdala; BG, basal ganglia; DMHN, dorsomedial hypothalamic nuclei; HB, habenular nucleus; HiP, hippocampus; HYP, 
hypothalamus; ipRGCs, intrinsically photosensitive retinal ganglion cells; LH, lateral hypothalamus; NAc, nucleus accumbens; NTS, nucleus of the solitary tract; OC, optic chiasm; 
PAG, periaqueductal gray; PB, parabrachial nucleus; PFC, prefrontal cortex; PiN, pineal gland; PvN, paraventricular nucleus; RGCs, retinal ganglion cells; S1 and S2, somatosensory 
cortex; SCN, suprachiasmatic nucleus; SO, supraoptic nucleus; vLPO, ventrolateral preoptic nucleus; vTA, ventral tegmental area.
Retrograde tracing experiments in animals and neuroim-
aging analysis in humans helped to identify their neuronal 
correlates, confirming that ipRGCs project directly to the 
SCN through the retinohypothalamic tract, but also show a 
widespread brain projection pattern from and to the SCN, 
which includes other hypothalamic nuclei, thalamic, stri-
atal, brainstem, and limbic structures (Figure 2).7,11,12 Direct 
projections of ipRGCs to the amygdala (AMY) have been 
described in rodents, and a retina–AMY functional pathway, 
passing through the superior colliculus and thalamus, has also 
been found in humans.13 More, the AMY, the hippocampus 
(HIP), and the HYP are secondarily influenced by the NIF 
system by the locus coeruleus, which also receives projec-
tions from the SCN.13,14 These brain areas, which represent 
the neural circuits for the emotional and nonvisual cognitive 
information processing, and also for the circadian regula-
tion of arousal, are selectively and wavelength dependently 
activated by acute light exposure, showing an increase in 
activity following blue light.10,15
Speculatively, light inputs to SCN also involve the dopamin-
ergic mesocorticolimbic pathway, also called the reward circuit, 
which is also indicated as the common neuroanatomical and 
functional correlate of pain and depression.16 The core of the 
brain reward/aversion system is the ventral tegmental area and 
its projections to the nucleus accumbens (NAc), which sends 
the information to the subcortical limbic areas, like the AMY, 
the HIP, and the HYP, and then to the prefrontal cortex and the 
anterior cingulate cortex for processing.17 Brain endogenous 
opioids and dopamine (DA) pathways mainly regulate the activ-
ity of NAc neurons and the release of DA contributing to shape 
the behavioral response to rewarding or aversive stimuli.18
The diurnal variation of DA transmission in the meso-
corticolimbic structures is dependent on the SCN and clock 
genes expression, thus supporting a functional correlation 
between the anatomical substrates for mood and mood-related 
symptoms, reward, and light stimuli.19,20 An integrated view 
of the anatomical network of NIF, mood, and reward signals 
is reported in Figure 2.
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Brief NGF and BDNF neurobiology
The nerve growth factor (NGF) was discovered in the 1940s 
by the Nobel Price winners Rita Levi-Montalcini and Stanley 
Cohen, and it represents the first factor showing survival and 
differentiative effects on neuronal cells.21 Nowadays, NGF is 
known to be a member of a group of molecules sharing struc-
tural and functional activities, including the brain-derived 
neurotrophic factor (BDNF), and that are collectively named 
neurotrophins (NTs).22 Both NGF and BDNF are involved in 
the regulation of central nervous system development, and 
extend their survival, protective, and regenerative action on 
immature and mature neuronal cells during the entire life 
span, and even in pathological conditions.22
In mammalian brain, these two NTs and their receptors are 
distributed in all the forebrain areas. Concerning NT mRNAs, 
they were originally localized in the HIP and cortex, and lately 
in the striatum, the HYP, the brainstem, and pituitary. This dem-
onstrated the synthesis of NTs in the brain, further suggesting 
how their local production might serve, beyond other things, 
to regulate the activities of interneurons, and/or the release of 
other factors/hormones via autocrine/paracrine mechanism (as 
reviewed by Sofroniew et al,22 Aloe et al,23 and Cirulli et al24).
Specific tyrosine kinase receptors, the TrkA and TrkB, 
mediate, respectively, most of the NGF and BDNF actions 
on their targets, but all the NTs also bind to a membrane 
glycoprotein p75 receptor (p75NTR), which can activate Trk-
convergent or Trk-divergent pathways.25 Indeed, NTs binding 
to Trks alone or Trk/p75NTR conjointly trigger a complex net-
work of intracellular signaling cascades, including induction 
of transcription factors (eg, c-fos), different classes of serine/
threonine-selective protein kinases (eg, mitogen-activated pro-
tein [MAP] kinases), as well as intracellular tyrosine kinases, 
which result in survival and trophic effects.
Different intracellular signals can be mediated by 
p75NTR, which can activate survival through the nuclear 
factor-κB pathway, and antagonizes the actions of TrkA 
through the JUN N-terminal kinase and RHOA pathways. 
Moreover, it has been found that the precursor NGF and 
BDNF forms also exert biological activity, and chiefly, acti-
vate apoptotic signals in neurons by binding the p75NTR/
sortilin complex.12,26
In line with this, the increased levels of proNTs associated 
with an unbalance of Trks/p75NTR are considered as part of a 
pathological cycle, which induces neuronal degeneration and 
results in impairment of brain and cognitive functions.27,28
Besides their action as survival factors, NGF and BDNF 
affect neurotransmitter synthesis and release influencing 
the activity-dependent synaptic plasticity, but also take part 
in the reorganization of the neuronal network induced by 
memory and stress, as well as in depression and following 
drug administration.29,30
The ability of NTs to stimulate survival of neuronal pre-
cursors and neurogenesis and modulate gliogenesis further 
contributes to support the NGF and BDNF involvement in 
the regulation of new born cells and connections generated by 
experiences and adaptation, and in the repair and connectivity 
rearrangement in pathological conditions.31
It is relevant to note that NGF and BDNF are synthesized 
in an activity-dependent manner and released upon neuron 
depolarization, and that they retrogradely and anterogradely 
act on presynaptic and postsynaptic neurons, respectively, 
but also exert autocrine and paracrine influence on the sur-
rounding cells.29 Further, it has been observed that NGF is 
able to stimulate BDNF synthesis and/or release in vivo and 
to induce BDNF and NT3, another NT, release in vitro as a 
consequent of TrkA activation.32,33
On the contrary, BDNF-induced release of NT3 in PC12 
cells is mediated by p75NTR activation but not by Trks, 
indicating that the changes in one NT expression might 
affect the synthesis of the other NTs, and that NTs release 
is dependent on the relative expression of Trk/p75NTR.34 
In addition, the NTs-induced enhancement of their own 
synthesis occur in autocrine or paracrine manner implying a 
potential feedback mechanism relevant to synaptic plasticity 
and activity-dependent functions such as memory formation, 
learning, and adaptation to environmental change.
To strength this notion, the modification of NTs and 
NT receptors distribution in the brain, as well as changes in 
NGF or BDNF concentration in serum, is strictly associated 
with cognitive and emotional performance in experimental 
animals and humans, and with antidepressant (AD) and/
or physical therapies supporting the concept of the “neu-
rotrophic hypothesis” of mood-related disorders.
Furthermore, in the past years, the emerging contribution 
of visual system in the regulation of mood and cognition 
has offered the possibility to prospect a more integrated 
view of the NTs in affective neuroscience, and in the clini-
cal approach to mood-related disorders, which includes the 
anatomical and functional interplay between the sensitivity 
and body response to light and the NTs anatomical and 
functional pathways.
NGF and BDNF in the retina– 
brain pathways
A large amount of investigations demonstrated the role played 
by NTs in the development and functional maintenance of 
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the visual system.35 Both NGF and BDNF and their receptors 
are expressed in the retina, optic nerve, the visual cortex, 
and the geniculate nucleus, where they regulate the prolif-
eration, neurite outgrowth, and survival of cells.36 RGCs 
depend on the retrograde transport of NTs produced by the 
central targets, although both NGF and BDNF also exert 
paracrine and autocrine actions in the retina and the retinal 
recipient areas.37,38 Both exogenous and endogenous NTs 
can be anterogradely transported and therefore influence 
the survival of postsynaptic neurons and the development 
of synapses.38 Peculiarly, in RGCs, the NTs are not rapidly 
degraded after internalization, but they are differently sorted 
by a mechanism regulated by the Trks, so that NGF is mainly 
targeted to lysosomes, while BDNF is recycled to the surface 
membrane. NT receptors are also rapidly recycled to the 
cell surface, implying a regulation of receptor densities, and 
thus having a significant impact on the signals of survival 
or differentiation.39,40 The anterograde transport and the 
mechanism of NTs release at the postsynaptic levels also 
influence NTs produced in the retina, and in turn, the same 
retina/optic nerve pathways.
In this context, it is relevant that NGF and BDNF are 
synthesized in the SCN, and changes in circadian rhythmicity 
are observed when they are injected into the SCN or intracere-
broventricularly, suggesting to be implicated in the regulation 
of the circadian clock.41–45
Historically, the anatomical evidence that demonstrated 
a dense expression of p75NGFR in the SCN was thought to 
explain the observed NGF, and subsequently, BDNF effects.46 
Actually, the functional relevance of p75NGFR in the SCN is 
controversial, since the p75NTR in this nucleus is localized 
on the axon terminals of RGC and basal forebrain neurons 
and does not identify vasoactive intestinal polypeptide (VIP) 
neurons as initially suggested by Kiss et al.47 Null mutation 
of p75 gene in mice does not alter circadian rhythms of 
behaviors in constant dark but decreases phase shifts induced 
by brief pulses of light, indicating that the lack of p75NTR 
might be compensated by other mechanisms.48
Indeed, studies using the lesions of cholinergic projections 
to the SCN originating in the basal forebrain, and particularly 
in the nucleus basalis of Meynert and septum – the prefer-
ential NTs-responding neurons in the brain – demonstrated 
a role of p75NGF-cholinergic neurons in the regulation of 
SCN functions. However, these studies also show that residual 
p75-immunoreactive terminals from the retina – which 
might be less accessible to toxin-induced lesion – and/or 
non-cholinergic retinohypothalamic (RTH) fibers could be 
necessary to maintain a functional circadian clock.49,50
VIP and Calbidin d28k neurons, for example, are 
not affected by cholinergic toxin injection in the SCN or 
intracerebroventricular injection, but since NGF is able to 
stimulate VIP synthesis and to protect VIP neurons from 
damage, the possible involvement of Trk-mediated actions 
is conceivable.49–52
Further, glutamate and gamma-aminobutyric acid 
transmission have been demonstrated to contribute to 
the NTs-mediated effects on visual system, and to medi-
ate the light-induced activation of c-fos, extracellular 
signal-regulated kinase (ERK) 1/2, and clock genes in the 
SCN.53,54
NTs also affect the response to light by the activation 
of c-fos, and ERK1/2 in the SCN.55 These data associated 
with the evidences that both the TrkA and TrkB receptors 
are expressed in the SCN, and that the K252a – an inhibitor 
of the Trk family of NT receptors – blocks light-induced 
phase shifts when injected in the SCN, further support the 
functional involvement of Trk receptors in the light-induced 
response in brain.45,55
It is worth to note that the Trk receptor expression is 
regulated by NTs, and that in turn, Trks can determine the 
biological outcome of p75NTR signaling, implying that 
the variation of local NGF and BDNF levels in SCN might 
correspond to changes in the receptor-mediated light signal 
transmission.56
To strength this notion, Baeza-Raja et al57 have recently 
observed that the expression of NTs and their receptors 
fluctuates in SCN during the light/dark cycle. Chiefly, 
these authors show that while the expression of NGF, 
p75NGFR, and TrkA oscillates in phase with clock genes 
during the 24 hours, the TrkB levels are unchanged. On 
the contrary, BDNF shows a different pattern with higher 
expression levels during the subjective night and the 
lower ones during the subjective day. The circadian NTs 
signaling pattern is also observed in the liver, indicating a 
functional link between the SCN activity and the regulation 
of peripheral NTs.57
Interestingly, the NGF and BDNF levels in the serum 
and saliva of healthy men and women are also subjected to 
daily fluctuation, and both the saliva and serum NT levels 
can be modulated by light.58 These data further indicate a 
correspondence between the brain and the peripheral release 
of NTs, and might support their role as physiological markers 
of the light-induced rhythmicity.
Similar to what occurs in SCN, a circadian pattern with a 
night peak of BDNF protein is also observable in the retina, 
geniculate nucleus, and the visual cortex.32,59 These data 
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suggested that the low levels of BDNF during the subjective 
day might be not sufficient to activate the TrkB cascade, and 
therefore unable to transmit entraining light signals by retina 
pathways, or in other words, the BDNF secreted at night may 
be required for light-induced phase shifts.
On the other hand, the NGF trend shows a pick at the 
subjective day (CT8), and during the night (CT20), and fol-
lows the profile of clock genes, indicating a direct relationship 
between NGF and the SCN activity. In line with this, NGF 
induces a phase shift of free-running rhythms similar in both 
direction and circadian phase dependence to light stimuli, 
when injected at different time points of the circadian time 
implying that NGF stimulates neuronal pathways, which are 
coherent with light stimuli.43,44
The recent evidences that NGF administrated on ocular 
surface is able to exert effects in the brain might indirectly 
support this suggestion. Indeed, it has been demonstrated 
that when ocular administrated in form of eye drops (oNGF), 
NGF – probably through a trans-conjunctival/trans-scleral 
route – reaches the retina and the optic nerve and produces 
effects in the primary visual areas of visual cortex and 
geniculate nucleus.32
Subsequent studies revealed that oNGF can extent its 
trophic, differentiative, and regulatory actions on several 
forebrain structures, and similar to intracerebroventricularly 
injected NGF, oNGF regulates acetylcholine synthesis, 
induces recovery of damaged brain cholinergic neurons, and 
stimulates neurogenesis.28,31,32,60
Although different anatomical connections between the 
eyes and the brain, including those via nasal and nasolac-
rimal ducts, could mediate the effects of oNGF, the results 
of studies using radiolabeled NGF and c-fos expression as 
markers of neuronal activation support the involvement 
of retinal pathways. Indeed, NGF-I125 is found in the 
retina and optic nerve when administrated as eye drops 
indicating the transport through the RGC axons as also 
previously reported.32,39 The time-dependent activation of 
primary visual areas has been confirmed by the analysis 
of c-fos distribution, which also reveals the activation of 
several limbic areas, including the SCN, the supraoptic 
nucleus, and the paraventricular hypothalamic nucleus, 
demonstrating the involvement of the retinohypothalamic 
pathways.61
In parallel to increased NGF levels and the effect on 
the Trk and p75NTR expression, oNGF also stimulates 
the BDNF at both mRNA and protein levels in the retina 
and results in changes in BDNF in the HIP, septum, and 
HYP further supporting the central effects of ocular-
applied NGF, and a possible cross talk between BDNF 
and NGF signaling in the retina and retinal recipient brain 
areas.28,32,60
Although future studies are necessary to better charac-
terize the effects of oNGF on the SCN, and to disclose its 
potential role in the regulation of the circadian clock, it is 
possible to speculate that through its direct or indirect actions 
on other factors known to regulate light response, including 
BDNF, treatment with oNGF might also be useful in reset-
ting the alteration of circadian rhythms and behaviors in 
pathological conditions.
NT-related hypothesis of mood-
related disorders
In the past 30 years, a large amount of data from animal 
neurobehavioral models, human postmortem studies, brain 
imaging investigations, and genetic researches have dem-
onstrated the involvement of NTs in depression, NGF and 
BDNF in particular, and generated the “neurotrophic theory” 
of affective spectrum disorders.
This theory has initially been based on the assumption that 
the abnormal neuronal and glial densities and architecture 
observable in patients with psychiatric disturbances, includ-
ing depression, might depend on reduced neurotrophic sup-
port, and thus on the NGF- and BDNF-mediated protective 
and reparative actions.62–65
Studies on animal models support this hypothesis demon-
strating the correlation between NGF and BDNF expression 
in brain and depressive behaviors, the response to AD treat-
ments, and the sex-related differences in the vulnerability 
to depression.66
The study of pathological effects of acute and chronic 
stress, and environmental changes have also highly con-
tributed to disclose the role of NTs as markers and/or risk 
factor for mood disorders and generate an integrated model 
in which the NTs-induced brain plasticity and connectivity 
rearrangement are directly involved in the brain adaptation 
and resilience and show that stimuli of psychological nature 
might be implicated in the mechanisms triggering NGF and 
BDNF release.23,67
The model of early life stress in animals, including 
maternal separation, has also been used to demonstrate the 
role of NTs in the development of anxiety-related behaviors, 
and therefore to identify NGF and BDNF as biomarkers for 
emotional and mood disorders associated with events occur-
ring during childhood.24,62,68 Studies on humans contribute to 
consolidate the “neurotrophic model” by linking neurotrophic 
factors with the mechanisms of action of drugs used for the 
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treatment of these disorders and the epigenetic and genetic 
susceptibility to develop mood disturbances.69–71 In particular, 
patients with major depression show significant lower NGF 
and BDNF levels in serum, and changes in plasma and serum 
NGF and BDNF occur after AD treatments among major 
depressive disorder patients.72,73
Genetically, a functional variant of BDNF at codon 66 
(val66met) has been identified with the Met allele that results 
in abnormal intracellular packaging and secretion of BDNF, 
and it is associated with poorer episodic memory and reduced 
hippocampal N-acetyl aspartate.74,75 This BDNF val allele is 
reported to be a possible risk locus for bipolar disorder, but stud-
ies in Asian populations have not observed this association.76,77 
Jiang et al found that met66 variant is a risk allele for anxiety, 
while a single-nucleotide polymorphism in the BDNF exon I 
promoter that decreases promoter activity, -281 C4A, may be 
protective against anxiety disorders and major depression.78
Like BDNF met66, also, NGF val35 is thought to affect 
intracellular processing and secretion of the NGF protein, 
and NGF rs6330 is associated with changes in NGF and 
NGF receptors in the plasma relatively to the homozygotes 
CC or CT and TT genotypes, in both psychiatric patients and 
healthy subjects.79
Sex differences in the daily NGF and BDNF levels in 
serum of healthy subjects and psychiatric patients further 
support the role of NTs in the regulation of physiological 
and psychological dimensions of mood.80–82
Chronopathology and 
chronopharmacology of mood-
related disorders
The first studies on the role of the chronobiological factors 
in mental diseases were performed in the 1970s.83 However, 
just in the past 30 years, research was developed, and more 
relevant results were in the concept of seasonality and the 
demonstration of a relationship between circadian patterns 
and psychiatric disorders. Seasonal fluctuation of mood 
is observed in patients affected by the main psychiatric 
disorders, even though it is particularly evident in subjects 
affected by mood-related disorders.84 In Diagnostic and 
Statistical Manual of Mental Disorders, fifth edition, “sea-
sonal pattern” is a specifier applied to the pattern of major 
depressive episodes or to the presence of at least one type of 
episode (mania, hypomania, depression) within the diagnosis 
of recurrent major depressive disorder or bipolar disorder, 
respectively.85 Its essential feature is the onset and remission 
of the various episodes at characteristic times of the year. 
In most cases, major depressive episodes begin in fall and 
winter, directly related to day length decreasing, and remit in 
spring, as day length begins to increase.85,86 These episodes 
are often characterized by prominent energy, hypersomnia, 
overeating, weight gain, and a craving for carbohydrates.85 In 
the study by LeGates et al, a direct association between dimin-
ished light exposure and mood functions was demonstrated. 
What is more, this association was clearly mediated by the 
ipRGCs.87 With regard to bipolar disorder, a profound switch 
in mood between periods of mania and depression has also 
been reported.88 As for major depression, in most cases, 
shifts to the depressive phase have been observed to begin in 
autumn as day length decreases and often persist throughout 
the winter. By March, when day length begins to increase, 
hypomanic/manic episodes become more prevalent, a phe-
nomenon nicknamed “March madness”.86,89,90 At the basis of 
these two seasonal forms of depression, two major hypoth-
eses have been postulated: altered pineal gland melatonin 
daily rhythms and circadian phase shift (for a review, see 
LeGates et al86). Apart from seasonal forms of depression, 
monthly and circadian biological clock impairment have also 
been described in this disorder. Circadian disturbances of the 
main physiological functions have widely been reported in 
patients with nonseasonal depression, including increased 
mean core temperature and decreased period amplitude.91–93 
Compared with healthy subjects, patients with depression also 
show a circadian oscillation in plasma cortisol, norepineph-
rine, and prolactin, as well as abnormal patterns of melatonin 
secretion.94,95 With regard to depressive symptomatology, the 
majority of patients have been shown to present a daily pat-
tern of symptoms, usually more severe in the morning. Up to 
90% of these patients report an increase in nocturnal activity, 
which is accompanied by a decrease in sleeping time and the 
extended exposure to artificial light at night, while only a 
minority of them (6%–29%) report hypersomnia.96 Objective 
sleep measures are also disturbed.97 A phase-advance pattern 
of rapid-eye-movement activity and changes in dream experi-
ence are frequently observed, and as theorized by Freud, “… 
we must recognize in the dream, the guardian of sleep …”, 
a biological function and signal of psychophysical balance 
in sleep maintenance.98,99 Depressed patients also differ in 
sustained alertness over the 24-hour cycle, specifically with 
a reduced daytime alertness, compared with normal.100 More-
over, diurnal patterns of motor activity tend to differ between 
patients with mood disorders and healthy subjects.101 Reaction 
time and cognitive performance are impaired in morning test-
ing but not evening testing.102
Of note, circadian disturbances have been demonstrated to 
affect treatment response and clinical outcome, and this is not 
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only in depression.103 Indeed, many drugs show effects/adverse 
events that vary over the 24 hours of a day, and these varia-
tions represent true circadian rhythms in response (eg, they 
persist in constant environmental conditions). Besides, drug 
kinetics that govern disposition of drugs (and even target organ 
sensitivity) show circadian rhythms, and at least some of them 
are under the control of molecular clocks.104
To date, chronotherapeutics has been shown to be particu-
larly effective in the treatment of allergic rhinitis, arthritis, 
asthma, cancer, myocardial infarction, peptic ulcer disease, 
and stroke.105 In the treatment of depression, the word “chro-
notherapeutics” has taken on a broader significance referring 
not only to a treatment scheduling corresponding to a specific 
patient’s biological clock but also to a controlled exposure 
to various environmental stimuli and medications acting on 
biological (circadian) rhythms, in order to achieve targeted 
therapeutic effects.84
A circadian rhythm in the effects/adverse events of 
a number of mental health medications, including ADs and 
mood stabilizers, has been demonstrated.106 These rhythms 
seem to represent endogenous circadian rhythms resulting 
from the rhythmicity in drug susceptibility of the brain, 
which is not dependent on drug kinetics but on rhythms 
of neurotransmitters, receptors, and second messengers.106 
Back in 1978, the potent norepinephrine uptake blocker 
lofepramine was shown to present a greater AD effect dur-
ing a 3-week course of therapy when administered at 12 am 
than when administered at 8 am or 4 pm.107 In the study by 
Nagayama et al, the AD effect of the 5-HT blocker clomip-
ramine during 4 weeks of therapy varied depending on the 
time of administration.108 In this case, administration at noon 
was more effective than administration in the morning or in 
the evening. It has been observed that the norepinephrine and 
5-HT systems in the brain present diverse circadian rhythms, 
with a peak in the release of these two neurotransmitters 
during the middle dark period for the former and at noon 
for the latter. This difference could be at the basis of the 
24-hour rhythm change in the efficacy of the two tricyclic 
ADs, although the literature contains only scattered reports 
that have failed to confirm a circadian rhythm in the effects/
adverse events of the various ADs.106,109,110
NGF and BDNF as 
neuromodulators of 
chronotherapeutics of depression
As mentioned earlier, in the treatment of depression, 
chronotherapeutics also refers to interventions known to 
modulate the circadian clock. In a microarray study including 
12,000 transcripts, Li et al observed widespread changes 
in cyclic gene expression in six regions of postmortem 
brain tissue of depressed patients matched with controls.111 
Specifically, they showed an abnormal phasing of circadian 
gene expression in patients, with the most robust change 
seen in the anterior cingulate. In fact, interventions able to 
induce phase shift (generally a phase advance) in circadian 
rhythms have been demonstrated to have AD effects.112 
These interventions encompass both non-pharmacological 
and pharmacological strategies. Among the former, sleep 
deprivation therapy (keeping patients awake for ∼36 hours), 
sleep phase advance (setting sleep time earlier and advanc-
ing bedtimes over subsequent nights), and morning bright 
light therapy (10,000 lux) have been shown to have the 
most robust AD properties.112–115 Their effect is claimed to 
be rapid but transient, however, with the possibility to be 
stabilized by combinations of the different chronotherapeutic 
interventions among themselves and/or with conventional 
psychiatric treatments (for a review, see Wirz-Justice113). 
In this regard, adjunctive triple chronotherapy (combined 
total sleep deprivation, sleep phase advance, and bright light 
therapy) has recently been demonstrated to induce a rapid 
improvement in depressive symptoms in drug-resistant mood 
disorders and acutely suicidal depressed in-patients without 
early relapse.116,117 Remarkably, all these interventions have 
been shown to directly act on clock gene machinery. Studies 
of clock gene expression in the mice brain suggest that sleep 
deprivation can produce rapid (within hours) alterations.118,119 
Sleep phase advance, morning bright light therapy, and morn-
ing “blue” light stimulation have also been reported to affect 
daily clock gene expression measured in peripheral human 
blood.120,121 Regarding pharmacological strategies, there is 
evidence that the selective serotonin reuptake inhibitor drug 
fluoxetine modulates the activity of the circadian biologi-
cal clock, via phase advance in the firing of SCN neurons, 
further increasing the expression of various clock genes in 
the mice brain.122,123 Agomelatine, a novel dual melatonergic 
and specific serotonergic AD, can also cause phase-advance 
shifts in both mice and hamster brain when administered at 
specific times of day.124–126 Potential actions of agomelatine 
on clock gene expression have not been reported so far. Using 
neuronal cell cultures, low doses of the rapid-acting AD 
ketamine, a noncompetitive N-methyl-d-aspartate receptor 
antagonist, have been shown to blunt the amplitude of the 
transcription of different clock genes.127 More recently, one 
study has reported the effect of escitalopram on circadian 
genes in subjects with major depressive disorder.128 Of 
note, phase-advance shift of all these non-pharmacological 
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Figure 3 Schematic illustration of the hypothesis of NGF and BDNF involvement in the mechanism of action of ADs.
Notes: The inhibition of GSK-3 and HDACs is indicated as the two main pathways through which ADs regulate the transcription and expression of factors critically 
involved in neuroprotective, neurotrophic, anti-inflammatory, neurogenic, and angiogenic functions, thus resulting in the effective treatment of mood disorders. Along with 
these factors, NGF and BDNF might contemporaneously be regulated by, and induce, GSK-3 inhibition, and/or potentiate the effects of ADs action by activating MeK/eRK 
pathways. The ADs/neurotrophin signaling cascade is suggested to influence the different aspects of mood disorders, including circadian rhythm alteration, by stimulating 
neuronal survival and plasticity, inducing neurogenesis, and counteracting the pathological mechanisms, which may trigger and/or aggravate mood alterations, such as brain 
inflammation and drug abuse.
Abbreviations: ADs, antidepressants; BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; GSK-3, glycogen synthase kinase-3; 
HDACs, histone deacetylases; MeK/eRK, mitogen-activated protein kinase kinase/extracellular signal-regulated kinase; MMP, matrix metalloproteinase; NGF, nerve growth 
factor; Pi3K, phosphatidylinositol-3-kinase; veGF, vascular endothelial growth factor; vPA, valproate.
and pharmacological interventions is contrasted with those 
of the mood stabilizers lithium and valproate, which can 
induce a phase delay.129,130 However, in clinical studies, both 
lithium and valproate have their principal effect on mania 
(and prevention of manic relapse) rather than acute depres-
sive states.131 Lithium has also been shown to modulate 
multiple members of clock gene machinery.132 Noteworthy, 
glycogen synthase kinase-3β (GSK-3β), a key component 
of the mammalian circadian clock able to affect circadian 
rhythm generation by modifying the stability of circadian 
clock molecules, has been indicated as a common molecular 
target for many of the aforementioned chronotherapeutic 
interventions.133,134 Sleep deprivation response rates have 
been reported to be higher in depressed patients who carry 
a gene promoter polymorphism (rs334558) for decreasing 
GSK-3β activation.71,113 Lithium, valproate, serotoniner-
gic ADs, as well as agomelatine and low-dose ketamine 
increase GSK-3β phosphorylation/inactivation.134 Through 
the inhibition of GSK-3β via multiple signaling cascades 
such as the phosphatidylinositol-3-kinase (PI3K)/Akt and 
the MAP kinase kinase (MEK)/ERK pathways, all these 
treatments are hypothesized to regulate the transcription and 
expression of different neurotrophic, angiogenic, and neuro-
protective proteins (for a review, see Chiu et al135). Valproate 
has also been shown to act through the inhibition of histone 
deacetylase.136 Both PI3K/Akt and MEK/ERK pathways 
have, as a downstream target, the cyclic adenosine mono-
phosphate response element transcription factor (CREB). 
When activated through phosphorylation, CREB modulated 
the expression of neurotrophic and cell-protective proteins, 
such as BDNF, NGF, and Bcl-2.137,138 Interestingly, BDNF 
and NGF have been reported to function as both downstream 
molecules resulting from the inhibition of GSK-3β and 
upstream signals able to inhibit this molecular pathway.139 
Based on these evidences, it is possible to hypothesize an 
integrated AD/NTs cascade which might influence the dif-
ferent aspect of mood disorders, including circadian rhythm 
alteration, as illustrated in Figure 3. Indeed, a plethora of 
studies have reported significantly lower BDNF and NGF 
peripheral levels in patients with major depression.69,140 
Some clinical studies have evaluated the changes in plasma 
or serum BDNF and NGF levels before and after AD treat-
ments among patients with major depressive disorder, and 
most studies report increases in the BDNF levels following a 
course of AD treatment.73 With regard to NGF, almost all the 
researches have revealed no statistically significant difference 
before and after treatment.72 With regard to pharmacological 
and non-pharmacological chronotherapeutic interventions, 
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escitalopram, ketamine, lithium, and sleep deprivation have 
all been demonstrated to increase BDNF peripheral levels 
in patients with major depression.141–144 The improvement 
of depressive symptoms with escitalopram coincided with 
significant improvements in the recall of both the quantity 
and quality of dreams, and dreaming, therefore, could be 
considered a biomarker of the efficacy of AD therapy, also for 
its evidence of chronobiological trends.98,145 Animal models 
have also confirmed a BDNF change in rat HIP following 
agomelatine, while treatment with escitalopram affects 
BDNF expression in HIP and NGF in the cortex but not in 
other brain areas and serum.146,147 In a rat model of depression, 
Angelucci et al found that treatment with lithium alters the 
concentrations of NGF and BDNF in the HIP, frontal cortex, 
occipital cortex, and striatum, further supporting the role of 
NTs in the mechanism of action of ADs.148
With regard to non-pharmacological chronotherapeutic 
treatments, sleep deprivation in depressed patients has 
showed to produce a rapid increase in BDNF levels after 
a single treatment, and affect diurnal serum profile in 
responding patients.144,149 Light therapy has also showed to 
affect the diurnal trend of BDNF in the serum and saliva of 
young healthy women, and serum BDNF concentration in 
both men and women correlates with the sunshine hours per 
week throughout the year in both men and women, and with 
the seasonality of depressive symptoms.58,150 No data on the 
effects of sleep deprivation on the NGF diurnal and/or noc-
turnal profile in humans are available at present. However, 
studies in animals demonstrate that selective sleep depriva-
tion during the rapid-eye-movement sleep phase alters the 
expression of NGF and BDNF in brain of rodents, and that 
the effects of sleep deprivation on the NGF expression in 
somatosensory cortex of rats are influenced by the afferents 
input.151,152 Recently, Hight et al found that the expression 
of NGF in somatosensory cortical neurons is high during 
the dark phase, while it is low during the light phase.153 
On the contrary, high levels of NGF are expressed in the 
visual cortex during the light phase, further supporting the 
modulation of NGF expression in brain pathways activated 
by light stimuli, and therefore that changes in circulating 
or brain NGF and BDNF levels might reflex the light/dark 
cycle. Remarkably, a daily fluctuation of NGF and BDNF in 
human serum and plasma, also related to sex, has been found 
in healthy subjects.82 For example, diurnal BDNF rhythm 
was recently demonstrated in healthy men, where plasma 
BDNF and cortisol trends display highest concentrations in 
the morning, followed by a substantial decrease throughout 
the day, with lowest values at midnight.154 In women, the 
BDNF diurnal variations are also associated to the cortisol 
rhythm, but they are further influenced by ovarian function 
and contraceptive therapy.155 At variance, Piccinni et al did 
not find diurnal variation of BDNF in the plasma of women 
in either the follicular or luteal phase of the menstrual cycle, 
while variation in plasma BDNF levels was detected in men, 
with the peak at 8 am and nadir at 10 pm.156 BDNF fluctua-
tion in serum and saliva was also found in healthy women.58 
In agreement with Pluchino et al,155 this study shows that 
both the saliva and the serum BDNF levels in young women 
in their follicular phase of the ovarian cycle tend to decrease 
from morning to night and also shows that BDNF trend cor-
relates with morning–evening personality traits and habits, 
and it is affected by light therapy. These data have recently 
been reconfirmed by Tirassa and Iannitelli, in a study further 
exploring the sex difference in the daily trend of NGF and 
BDNF serum levels (unpublished). Specifically, the study 
shows that the BDNF levels in men increase from morning 
to night, while daily NGF presents the “V” shape trend 
already reported by Bersani et al,82 but serum NGF trend in 
both man and woman is affected by light exposure. While 
a number of studies are now available on diurnal variation 
of NTs levels, at present, only one study has investigated 
this same issue in patients with depression. In the work 
by Giese et al, diurnal BDNF oscillations in patients with 
major depression associated with therapeutic response (in 
both sexes) after partial sleep deprivation.144 Specifically, 
subjects identified as responders (after 2 weeks of treat-
ment) were associated with a daily change in serum BDNF 
at day 1 and even pretreatment, at baseline. This variation of 
peripheral BDNF concentration revealed characteristics of a 
diurnal pattern, whereas nonresponders did not exhibit diur-
nal BDNF variation. Together, all these findings emphasize 
the importance of a circadian NT rhythm in human health 
and well-being, while its absence seems to have a negative 
impact on successful depression treatment outcome. They 
further support a direct link between depression, biological 
clock, chronotherapeutics, and brain plasticity.
Conclusion
The data presented support the role of NGF and BDNF in 
the chronopathology and chronotherapeutics of mood, and 
therefore suggest these NTs as valuable biomarkers in human 
studies. Further, the fascinating hypothesis that ocular-
applied NTs (by stimulating the retinal pathways associated 
with NIF functions) might also reset circadian rhythms offers 
a new interesting field of investigation in neuroscience and 
psychiatry.
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